Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glypromate for prevention of neurocognitive decline after cardiopulmonary bypass surgery
ACTRN12608000168358Phase 3Active, not recruiting
- Sponsor
- Neuren Pharmaceuticals Limited
- Start
- Sep 2007
- Modality
- Small Molecules, Peptides
- Countries
- 3
01
Overview
Phase 3, randomised trial in Postoperative neurocognitive disorder (PND) comparing Glypromate with Placebo (2 arms). Primary endpoints: Reduction in cognitive decline using composite of 5 domain Z scores and Difference in Activities of Daily Living questionnaire composite scores. Started Sep 2007; status: active, not recruiting.
02
Drugs
glypromate
03
Conditions
Postoperative neurocognitive disorder (PND)
Beyond the preview
Go deeper on ACTRN12608000168358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12608000168358.